Roche

News

Ten years on, Roche jettisons InterMune and Esbriet in US

It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.

News

Graphic representation of an implant into an eyeball

FDA expands label for Roche's eye disease implant Susvimo

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

Roche's Parkinson's hope fails second clinical trial

Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.

Ten years on, Roche jettisons InterMune and Esbriet in US

FDA expands label for Roche's eye disease implant Susvimo

Boost to Enhertu's prospects as FDA clears Roche diagnostic

US/EU regulators start review of Biogen's high-dose Spinraza

Roche licenses Innovent ADC that could challenge Amgen drug

Roche's Parkinson's hope fails second clinical trial

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Roche

Editor's Picks